SILVER SPRING, Md., July 28 (Reuters) - King Pharmaceuticals (KG.N) failed to show a proposed imaging drug worked as well as an approved product in tests to diagnose heart disease, a U.S. advisory panel said on Tuesday. Company studies compared the CorVue injection to an approved drug, adenosine. Both drugs widen blood vessels so doctors can get a better look inside the heart when they run imaging tests such as CT scans. Advisers to the Food and Drug Administration voted 11-5 that King's studies did not show a high degree of similarity between images made using CorVue and others with adenosine.
